Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Eisai Co. Ltd (ESAIY)

Eisai Co. Ltd (ESAIY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ESAIY with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.3100 +14.00%
on 04/18/24
10.7600 -1.37%
on 05/06/24
+0.5630 (+5.60%)
since 04/05/24
3-Month
9.3100 +14.00%
on 04/18/24
11.3199 -6.24%
on 02/14/24
-0.3870 (-3.52%)
since 02/07/24
52-Week
9.3100 +14.00%
on 04/18/24
21.0000 -49.46%
on 06/09/23
-4.5070 (-29.81%)
since 05/05/23

Most Recent Stories

More News
Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi

Biogen's shares decline after approval of Alzheimer's treatment Leqembi, which modestly slows cognitive decline. Analysts see hurdles to the rollout.

ESAIY : 10.6130 (-0.81%)
BIIB : 218.92 (-1.13%)
LLY : 777.77 (+1.45%)
XLV : 142.57 (+0.83%)
ESALY : 61.5100 (-2.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 10.7903
2nd Resistance Point 10.7477
1st Resistance Point 10.6803
Last Price 10.6130
1st Support Level 10.5703
2nd Support Level 10.5277
3rd Support Level 10.4603

See More

52-Week High 21.0000
Fibonacci 61.8% 16.5344
Fibonacci 50% 15.1550
Fibonacci 38.2% 13.7756
Last Price 10.6130
52-Week Low 9.3100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar